Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition.
Episode 20 clarifies the selective role of thoracic radiation in extensive-stage small cell lung cancer. We distinguish consolidative treatment after a favorable systemic response from palliative treatment for symptoms or threatened thoracic function—two indications that may use the same machine but differ in intent, urgency, target, dose, and acceptable burden.
Using persistent thoracic disease after systemic therapy as the anchor, we weigh extracranial disease pace, functional trajectory, competing systemic risk, symptom risk, and whether a meaningful thoracic target can be treated safely.

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition.
Episode 19 examines the decision between prophylactic cranial irradiation and structured MRI surveillance in small cell lung cancer, including the role of hippocampal avoidance. We place the evidence in its imaging and treatment era rather than treating older trials as if every patient had modern brain MRI and dependable salvage access.
The discussion centers on shared decision-making: intracranial-control benefit, disease extent and response, surveillance reliability, neurocognitive risk, functional priorities, and the practical consequences of choosing observation or cranial treatment.

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition.
Episode 18 follows limited-stage small cell lung cancer from the start of chemotherapy through thoracic radiation planning and post-treatment decisions. We discuss treatment timing, fractionation, target construction, the use of pre- and post-chemotherapy disease information, image guidance, and how toxicity or interruptions change the plan.
The episode keeps the sequence coherent: choose a curative strategy the patient can complete, avoid losing clinically meaningful disease in the planning process, and reassess response before decisions about consolidation and brain-directed management.

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition.
Episode 17 establishes the foundations of small cell lung cancer care: pathologic confirmation, complete staging, mandatory attention to brain imaging, the rare role of surgery, and entry into curative treatment for limited-stage disease.
We focus on the decisions that prevent stage and intent errors—distinguishing limited from extensive disease, identifying when invasive staging or additional workup matters, and coordinating chemotherapy with thoracic radiation. The goal is a concise, board-ready framework that remains accurate when the clinical presentation is incomplete.

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition.
Episode 16 begins where definitive chemoradiation ends. We organize post-treatment care around three competing possibilities: eligibility for consolidation therapy, clinically important toxicity, and early relapse or progression.
The episode shows how to interpret symptoms and imaging without prematurely labeling every pulmonary change as radiation injury, how to stabilize and evaluate treatment-limiting toxicity, and how molecular findings, performance status, disease distribution, and prior therapy shape the next systemic or local treatment decision.

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition.
Episode 15 is a planning-focused guide to definitive radiation for stage III non-small cell lung cancer. We move from simulation and motion assessment to gross disease, nodal volumes, target margins, technique, image guidance, adaptive triggers, and plan appraisal.
The core challenge is not simply achieving coverage. It is building a defensible plan that reflects the actual disease map while controlling heart, lung, esophageal, spinal-cord, and treatment-time risks. We also discuss when anatomy or response has changed enough that the original plan should no longer be treated as valid.

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition.
Episode 14 builds the definitive treatment framework for unresectable stage III non-small cell lung cancer. We begin by confirming a curable nonsurgical disease state, completing stage-defining workup, and deciding whether the patient can safely complete concurrent chemoradiation or needs a modified sequence.
From there, we connect treatment intensity to radiation dose, systemic therapy, interruption management, post-chemoradiation consolidation, surveillance, and relapse. The emphasis is on preserving curative intent when appropriate while making frailty, toxicity, progression, and molecular findings explicit decision points.

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition.
Episode 13 is a three-block mock oral in localized and resectable non-small cell lung cancer. The cases move from surgery versus stereotactic radiation for peripheral disease, to central and ultracentral anatomy, and then to resectable nodal and superior sulcus disease with multimodality sequencing and postoperative decisions.
Pause before each model answer and give a structured response: state the diagnosis and known extent, name the management-changing unknown, separate operability from resectability, declare treatment intent, and carry the recommendation through evidence, planning, safety, surveillance, and salvage.

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition.
Episode 12 takes a selective, evidence-based approach to postoperative radiation therapy for non-small cell lung cancer. We reconstruct residual disease, margin status, nodal burden and geography, surgical quality, the preoperative disease map, competing systemic risk, cardiopulmonary reserve, and the target that would actually be treated.
The episode explains why improved mediastinal control after complete resection does not automatically translate into a survival benefit, and how to weigh that local-control gain against heart, remaining-lung, esophageal, and spinal-cord exposure.

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition.
Episode 11 examines trimodality therapy through the demanding example of a superior sulcus tumor. Before chemotherapy and radiation begin, the team must define thoracic-inlet invasion, nodal status, the feasibility of a margin-negative operation, the patient’s ability to tolerate that operation, and what the definitive fallback will be if surgery is cancelled.
We connect multidisciplinary selection to simulation, target design, organ-at-risk priorities, surgical timing, and continuity of curative treatment—so the sequence is a planned oncologic strategy rather than three disconnected modalities.